• Hub Login
  • Contact
  • Investors
  • Viveve Solutions
    • Viveve System
    • InControl by Viveve
  • Clinical Studies
  • About
    • Mission
    • Leadership
    • Careers
  • News
    • Blog
    • Media & Press
    • Investor News
    • Events
  • Testimonials
Select Page
Dev Site

A Global Women’s Intimate Health Company

Press Releases

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Publications
    • IR Calendar
    • Analyst Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Clinical Advisory Board
    • Medical Consultants
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Investor Presentation
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Publications
  • IR Calendar
  • Analyst Coverage
  • Email Alerts

Viveve to Host Conference Call to Provide Corporate Update and Second Quarter 2019 Results on August 8, 2019

Aug 1, 2019

Viveve Announces Top-line Results of LIBERATE-International Trial for SUI, Q2 Transition to New U.S. Commercial Model, and Pursuit of Financial and Strategic Alternatives

Jul 22, 2019

Viveve Announces FDA 510(k) Clearance of Viveve 2.0 Next Generation System in the U.S.

Jun 25, 2019

Viveve to Present at Raymond James Life Sciences and MedTech Conference

Jun 11, 2019

Viveve Reports First Quarter 2019 Financial and Operating Results

May 9, 2019

Viveve to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results on May 9, 2019

May 2, 2019

Viveve Announces CE Mark Clearance for its Next Generation 2.0 Platform in the European Union

Apr 11, 2019

Viveve Reports Fourth Quarter and Full Year 2018 Financial Results

Mar 14, 2019

Viveve Completes Enrollment in VIVEVE II Trial

Mar 11, 2019

Viveve to Host Conference Call to Discuss Fourth Quarter and Year-end 2018 Financial Results and Corporate Update on March 14, 2019

Mar 7, 2019
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...30

    Solutions

    • Viveve System
    • InControl Products
    • Common Conditions

    About

    • Mission
    • Leadership
    • Contact Us
    • Investor Information

    News

    • Viveve Blog
    • Events
    • News & Publications
    • Testimonials

    Resources

    • Hub Login
    • Careers with Viveve
    • Support Center
    Dev Site
    345 Inverness Drive South • Building B, Suite 250 • Englewood, CO 80112
    The Viveve® System is an internationally patented cryogen-cooled, monopolar radiofrequency (CMRF) energy-based device. It has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan. Country-specific approved indications include: • In Argentina the Viveve System is indicated for the treatment of urinary incontinence, vaginal laxity, and sexual function. • In Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Hong Kong, Japan, Mexico, Panama, Philippines, Singapore, Uruguay, and Venezuela the Viveve System is indicated for the treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function. • In the EU, Bahrain, Iceland, Korea, Kuwait, Lebanon, Liechtenstein, Norway, South Africa, Switzerland, and Ukraine the Viveve System is indicated for the treatment of vaginal laxity. • In Peru, Taiwan, and the United States the Viveve System is cleared for general surgical procedures for electrocoagulation and hemostasis.